<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022993</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGIN-IM</org_study_id>
    <nct_id>NCT04022993</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients</brief_title>
  <official_title>An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Insulin RinGlar® (&quot;Geropharm&quot;, Russia) Compared to Lantus® SoloStar® (&quot;Sanofi-Aventis Deutschland GmbH&quot;, Germany) in Type 1 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to approve non-inferior efficacy and safety of Insulin RinGlar®
      compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline in titer of antibodies to human insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events frequency and degree</measure>
    <time_frame>26 weeks (4+22 weeks)</time_frame>
    <description>Hypoglycemic episodes (glucose level &lt; 3.9 mmol/l) frequency; Occurrence of local reactions at injection sites; Occurrence allergic reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in HbA1c from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose Level</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in fasting plasma glucose level from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seven-Point Glucose Testing</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in seven-point glucose testing results from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Insulin Dose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in basal insulin dose per body weight (U/kg) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Insulin Dose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in total insulin dose per body weight (U/kg) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in overall treatment satisfaction (DTSQ score) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Glycated Hemoglobin Goals</measure>
    <time_frame>26 weeks</time_frame>
    <description>The frequency of achievement glycated hemoglobin goals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Glycated Hemoglobin &lt; 7%</measure>
    <time_frame>26 weeks</time_frame>
    <description>The frequency of achievement glycated hemoglobin &lt; 7% ( 7% inclusive)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lantus® SoloStar®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin RinGlar®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus Solostar, 100 Units/mL Subcutaneous Solution</intervention_name>
    <description>4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses</description>
    <arm_group_label>Lantus® SoloStar®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin RinGlar, 100 Units/mL Subcutaneous Solution</intervention_name>
    <description>4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses</description>
    <arm_group_label>Insulin RinGlar®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written consent

          -  Diabetes mellitus type 1 for at least 12 months prior to screening

          -  History of basis-bolus (multiple dose injection (MDI)) therapy in stable doses at
             least 30 days

          -  Glycated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values
             inclusive)

          -  Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive)

          -  Subject is able and willing to comply with the requirements of the study protocol

        Exclusion Criteria:

          -  Contraindication to the use of Insulin glargine

          -  Insulin resistance over 1.5 U/kg insulin pro day

          -  History of treatment any biosimilar insulin

          -  History of treatment any experimental drugs or medical devices for 3 months prior to
             screening

          -  History of treatment insulin pump for 90 days prior to signed written consent or
             indication for use insulin pump

          -  Presence of severe diabetes complications

          -  History of severe hypoglycemia during 6 months prior to signed written consent

          -  History of 15 or more episodes mild hypoglycemia during 1 month prior to signed
             written consent

          -  History or presence of uncontrolled diabetes mellitus for 6 months prior to screening

          -  History of administration of glucocorticoids for 1 year prior to screening

          -  Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum, etc.)

          -  History of autoimmune disease, except vitiligo and controlled autoimmune polyglandular
             syndrome (APS) types 1-3, except adrenal insufficiency

          -  History of hypersensitivity to any of the active or inactive ingredients of the
             insulin/insulin analogue preparations used in the trial, OR history of significant
             allergic drug reactions

          -  History of severe allergic reactions

          -  Pregnant and breast-feeding women

          -  Acute inflammation disease for 3 weeks prior to screening

          -  Deviation of the laboratory results conducted during the screening:

        Hemoglobin value &lt; 9,0 g/dl; Hematocrit value &lt; 30 %; ALT and AST value &gt; 2 folds as high
        as maximal normal value; Serum bilirubin value &gt; 1.5 folds as high as maximal normal value

          -  History of hematological disorders that can affect the reliability of HbA1c estimation
             (hemoglobinopathies, hemolytic anemia, etc.)

          -  Serious blood loss for 3 months prior to screening (blood donation, surgery procedure,
             etc.)

          -  Incomplete recovery after surgery procedure

          -  History of unstable angina, myocardial infarction, severe arrhythmia, heart failure
             III or IV NYHA for 1 year prior to screening

          -  History of stroke or TIA for 6 months prior to screening

          -  History of drug, alcohol abuse for 3 years prior to screening

          -  Inability follow to protocol

          -  History of oncological disease during 5 years prior to screening

          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg),
             hepatitis C (HCVAb) or syphilis (Treponema pallidum) antibodies at screening.

          -  History of transplantation, except 3 months after corneal transplant

          -  History or presence of a medical condition or disease that in the investigator's
             opinion would embarrass glycemic control and completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatyana L Karonova, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Almazov National Medical Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Hospital</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan Endocrinology Dispensary</name>
      <address>
        <city>Kazan</city>
        <zip>420073</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Research Centre (Moscow)</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A. Baranov Republic Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic Сomplex</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Diagnostic Center № 1</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital № 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic № 117</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EosMed</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pokrovskaya Municipal Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical City Hospital № 9</name>
      <address>
        <city>Saratov</city>
        <zip>410030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

